• 1. An integrated chip for immunofluorescence and its application to analyze lysosomal storage disorders
  Jie Shen,Ying Zhou,Tu Lu,Junya Peng,Zhixiang Lin,Yuhong Pang,Li Yu Lab Chip, 2012,12, 317-324
• 2. An atlas of endohedral Sc2S cluster fullerenes?
  Li-Hua Gan,Rui Wu,Jian-Lei Tian,Patrick W. Fowler Phys. Chem. Chem. Phys., 2017,19, 419-425
• 3. An anti-leakage liquid metal thermal interface material
  Kaiyuan Huang,Wangkang Qiu,Meilian Ou,Xiaorui Liu,Zenan Liao,Sheng Chu RSC Adv., 2020,10, 18824-18829
• 4. An intensified π-hole in beryllium-doped boron nitride meshes: its determinant role in CO2 conversion into hydrocarbon fuels?
  Luis Miguel Azofra,Douglas R. MacFarlane,Chenghua Sun Chem. Commun., 2016,52, 3548-3551
• 5. An air-stable organometallic polymer containing titanafluorene moieties obtained by the Sonogashira–Hagihara cross-coupling polycondensation?
  Alvin Tanudjaja,Shinsuke Inagi,Fusao Kitamura,Toshikazu Takata,Ikuyoshi Tomita Dalton Trans., 2021,50, 3037-3043

• Solvents and Organic Chemicals Organic Compounds Organic oxygen compounds Organooxygen compounds Ketones
• Solvents and Organic Chemicals Organic Compounds Organic oxygen compounds Organooxygen compounds Carbonyl compounds Ketones

Recent Advances in the Study of 1-(5-fluoro-2-hydroxyphenyl)butan-1-one (CAS: 575-67-7) in Chemical Biology and Pharmaceutical Research

The compound 1-(5-fluoro-2-hydroxyphenyl)butan-1-one (CAS: 575-67-7) has recently garnered significant attention in the field of chemical biology and pharmaceutical research. This molecule, characterized by its fluoro-hydroxyphenyl and butanone structural motifs, has demonstrated promising potential in various therapeutic applications. Recent studies have explored its synthesis, pharmacological properties, and mechanisms of action, positioning it as a candidate for further drug development. This research brief aims to summarize the latest findings related to this compound, highlighting its significance and potential impact on the field.

A key area of interest is the synthesis and optimization of 1-(5-fluoro-2-hydroxyphenyl)butan-1-one. Recent publications have detailed novel synthetic routes that improve yield and purity, addressing previous challenges in its production. For instance, a 2023 study published in the Journal of Medicinal Chemistry described a catalytic asymmetric synthesis method that enhances enantiomeric purity, a critical factor for its biological activity. These advancements not only facilitate larger-scale production but also enable more precise structure-activity relationship (SAR) studies.

Pharmacological investigations have revealed that 1-(5-fluoro-2-hydroxyphenyl)butan-1-one exhibits notable anti-inflammatory and antimicrobial properties. In vitro and in vivo studies have shown its ability to inhibit key inflammatory mediators such as cyclooxygenase-2 (COX-2) and nuclear factor-kappa B (NF-κB). Additionally, its antimicrobial activity against Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA), has been documented in a 2024 study in Bioorganic & Medicinal Chemistry Letters. These findings suggest its potential as a dual-action therapeutic agent.

Mechanistic studies have further elucidated the molecular interactions of 1-(5-fluoro-2-hydroxyphenyl)butan-1-one. Computational docking and molecular dynamics simulations have identified its binding affinity for specific protein targets, such as the bacterial enzyme dihydrofolate reductase (DHFR). This insight has paved the way for rational drug design efforts aimed at enhancing its efficacy and selectivity. Moreover, recent pharmacokinetic studies have evaluated its absorption, distribution, metabolism, and excretion (ADME) profiles, providing a foundation for future preclinical development.

In conclusion, 1-(5-fluoro-2-hydroxyphenyl)butan-1-one (CAS: 575-67-7) represents a versatile compound with significant therapeutic potential. Recent advancements in its synthesis, pharmacological characterization, and mechanistic understanding underscore its value as a candidate for further drug development. Ongoing research is expected to explore its applications in treating inflammatory diseases and bacterial infections, as well as its potential synergies with existing therapies. The continued investigation of this compound holds promise for addressing unmet medical needs in the chemical biology and pharmaceutical sectors.

• 443-09-4(1-(5-Fluoro-2-hydroxyphenyl)propan-1-one)
• 135276-47-0(1-(4-Fluorophenyl)-3-(2-hydroxyphenyl)propane-1,3-dione)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)